$PVLA insider trading
Over the last 12 months, Palvella Therapeutics insiders reported 3 buys totaling $850K and 11 sales totaling $8.6M across SEC Form 4 filings. 71% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $850K 3 events
- Sold · 12m
- $8.6M 11 events
- Events · 12m
- 14 Form 4 filings, grouped
- Insiders · 12m
- 4 distinct reporters
- 10b5-1 share
- 71% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | JENKINS GEORGE MD | ▼ Sale | 27,500 | $151.53 | $4.2M | -14.7% | plan · 9 tranches |
| Sep 2, 2026 | KIRITSY CHRISTOPHER PD | ▼ Sale | 313 | $157 | $49K | -55.6% | — |
| Aug 19, 2026 | Goin KathleenChief Operating Officer · O | ▼ Sale | 4,302 | $152.21 | $655K | -100% | plan · 5 tranches |
| Jul 15, 2026 | Goin KathleenChief Operating Officer · O | ▼ Sale | 4,302 | $149.28 | $642K | -100% | plan · 4 tranches |
| Jun 17, 2026 | Goin KathleenChief Operating Officer · O | ▼ Sale | 4,302 | $110.73 | $476K | -100% | plan · 3 tranches |
| Apr 15, 2026 | Goin KathleenChief Operating Officer · O | ▼ Sale | 4,302 | $127.24 | $547K | -100% | plan · 5 tranches |
| Mar 30, 2026 | JENKINS GEORGE MD | ▲ Buy | 445 | $112.3 | $50K | +0.2% | — |
| Mar 18, 2026 | Goin KathleenChief Operating Officer · O | ▼ Sale | 4,302 | $117.99 | $508K | -100% | plan · 3 tranches |
| Feb 27, 2026 | JENKINS GEORGE MD | ▲ Buy | 4,000 | $125 | $500K | +2.2% | — |
| Feb 27, 2026 | HERON ELAINE JD | ▲ Buy | 2,400 | $125 | $300K | +5.3% | — |
| Feb 18, 2026 | Goin KathleenChief Operating Officer · O | ▼ Sale | 4,302 | $79.4 | $342K | -100% | plan · 2 tranches |
| Jan 21, 2026 | Goin KathleenChief Operating Officer · O | ▼ Sale | 4,302 | $97.63 | $420K | -100% | plan · 2 tranches |
| Dec 17, 2025 | Goin KathleenChief Operating Officer · O | ▼ Sale | 4,302 | $96.47 | $415K | -100% | plan |
| Nov 19, 2025 | Goin KathleenChief Operating Officer · O | ▼ Sale | 4,302 | $86.23 | $371K | -100% | plan · 2 tranches |
Every $PVLA filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Palvella Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $PVLA feed.